Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Fortrea Holdings Inc. regarding a class action lawsuit due to alleged misleading statements and overestimations related to the company's financial projections and business model [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from July 3, 2023, to February 28, 2025, Fortrea Holdings Inc. made materially false and misleading statements, including: - Overestimating revenue contributions from long-term projects, known as Pre-Spin Projects, to the company's 2025 earnings [3]. - Overstating potential cost savings from exiting transition services agreements [3]. - Inflating previously announced EBITDA targets for 2025 [3]. - Overstating the viability of the company's post-spin-off business model and its financial prospects [3]. - Resulting in public statements that were materially false and misleading throughout the relevant period [3]. Class Action Details - The deadline for shareholders to register for the class action is August 1, 2025 [4]. - Shareholders who register will be enrolled in a portfolio monitoring software for status updates on the case [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, alleging that the company overstated cost savings and revenue projections related to its transition services agreements with Labcorp [1][2][4]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off from Labcorp Holdings Inc. in June 2023 [3]. Group 2: Allegations and Financial Impact - The lawsuit claims that Fortrea exaggerated the cost savings and margin improvements expected from exiting transition services agreements with Labcorp, as well as the revenue from pre-spin projects [4]. - Following a report from Jefferies on September 25, 2024, which indicated that the anticipated cost savings were not as significant as previously thought, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 financial results, revealing lower-than-expected revenue and profitability from pre-spin projects, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

Company Announcement - Fortrea will release its second quarter 2025 financial results before the market opens on August 6, 2025 [1] - A conference call will be held at 8:00 am ET on the same day to review the financial results and conduct a Q&A session [1] Participation Details - Participants can register online at the Fortrea Investor Relations website and are advised to join at least 10 minutes prior to the call [2] - A replay of the conference call will be available shortly after the event on the Fortrea Investor Relations website [2] Company Overview - Fortrea is a leading global provider of clinical development solutions to the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies [3] - The company offers phase I-IV clinical trial management, clinical pharmacology, and consulting services, leveraging over 30 years of experience across more than 20 therapeutic areas [3] - Fortrea operates in about 100 countries, providing focused and agile solutions to customers globally [3]

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings Inc. for allegedly misleading investors regarding its financial performance and projections following its spin-off from Labcorp Holdings Inc. [1][3][5] Group 1: Company Background - Fortrea Holdings was spun off from Labcorp Holdings in June 2023 as a standalone publicly traded company [3] - The company entered into transition services agreements with Labcorp to receive various administrative and IT support services [3] Group 2: Financial Performance - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not meeting prior expectations, leading to a significant stock price drop of $3.47 per share, or 25.05%, closing at $10.38 [4] - The company indicated that its Pre-Spin projects were underperforming, with less revenue and profitability than anticipated for 2025 [4] Group 3: Allegations in the Lawsuit - The complaint alleges that Fortrea overestimated revenue contributions from Pre-Spin projects and overstated potential cost savings from exiting transition services agreements [5] - It is claimed that the company's previously announced EBITDA targets for 2025 were inflated, misrepresenting the viability of its post-Spin-Off business model [5]

NEW YORK, July 15, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Fortrea Holdings, Inc. (NASDAQ: FTRE) securities between July 3, 2023 and February 28, 2025, both dates inclusive (the "Class Period"), of the important August 1, 2025 lead plaintiff deadline.So what: If you purchased Fortrea securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.What to do ne ...

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. ("Fortrea Holdings Inc." or the "Company") (NASDAQ: FTRE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fortrea Holdings Inc. investors who were adversely affected by alleged securities fraud between July 3, 2023 and February 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/psl ...

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, specifically related to the company's financial disclosures and performance claims [1][2]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off from Labcorp Holdings Inc. in June 2023 [3]. - Following the spin-off, Fortrea entered into transition services agreements (TSAs) with Labcorp, agreeing to pay for certain transitional services over a specified period [3]. Group 2: Allegations and Financial Performance - The lawsuit alleges that Fortrea overstated the cost savings and margin improvements expected from exiting the TSAs, as well as the revenue from pre-spin projects [4]. - On September 25, 2024, a report from Jefferies indicated that the anticipated cost savings from exiting the TSAs were not as significant as previously claimed, leading to a stock price decline of $2.73 per share, or over 12% [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 financial results, revealing lower-than-expected revenue and profitability from pre-spin projects, resulting in a further stock price decline of $3.47 per share, or over 25% [6].

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, specifically related to the company's financial disclosures and performance claims [1][2]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off from Labcorp Holdings Inc. in June 2023 [3]. Group 2: Allegations and Financial Performance - The lawsuit alleges that Fortrea overstated the cost savings and margin improvements expected from exiting transition services agreements with Labcorp, as well as the revenue from pre-spin projects [4]. - Following a report from Jefferies on September 25, 2024, which indicated that the anticipated cost savings were not as significant as claimed, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 results, revealing lower-than-expected revenue and profitability from pre-spin projects, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. ("Fortrea Holdings Inc." or the "Company") (NASDAQ: FTRE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fortrea Holdings Inc. investors who were adversely affected by alleged securities fraud between July 3, 2023 and February 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/psl ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fortrea Holdings, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 1, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - Investors who bought Fortrea securities between July 3, 2023, and February 28, 2025, may be eligible to join a class action lawsuit [1][2]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline [2]. - The lawsuit alleges that Fortrea made false and misleading statements regarding its revenue projections and cost savings, which inflated its EBITDA targets for 2025 [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen has been recognized as a Titan of Plaintiffs' Bar by Law360, highlighting the firm's expertise in this area [3].